Hosted on MSN2d
Zevra sells priority review voucher for $150m to support drug launches
Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...
FiercePharma3d
Zevra to net $150M from priority review voucher sale tied to Miplyffa approval
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...
The Pharma Letter3d
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.
MedCity News3d
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M
The priority review voucher awarded alongside the approval of Miplyffa will be sold for $150 million, Zevra announced Thursday. The buyer of the voucher was not disclosed. Celebration, Florida ...
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...
Zevra Therapeutics to sell Rare Pediatric Disease PRV for $150M
Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...
Nasdaq1mon
Zevra Therapeutics' MIPLYFFA™ Receives 2025 New Treatment Award at WORLDSymposium; Eight Abstracts Accepted for Presentation
Zevra Therapeutics, Inc. announced that it will receive a 2025 New Treatment Award for its product MIPLYFFA™ (arimoclomol) at the 21st Annual WORLDSymposium. Eight abstracts related to MIPLYFFA ...
The National Law Review3d
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
The PRV was granted to Zevra in September 2024 following approval by the U.S. Food and Drug Administration of MIPLYFFA (arimoclomol), which is indicated for use in combination with miglustat for ...
Nasdaq3d
Zevra Therapeutics Enters $150 Million Asset Purchase Agreement for Rare Pediatric Disease Priority Review Voucher
This non-dilutive capital will enhance Zevra's financial position and support its strategic priorities, including the commercial launches of its therapies MIPLYFFA™ and OLPRUVA®, as well as ...